Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002453 (amenorrhea)
 6,245 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Most adolescent gynecological problems are related to sexual activity or the development or failure of hypothalamic-pituitary-ovarian-uterine activity. The 1st years of menstruation are usually anovulatory resulting in variable periods of amenorrhea which corrects itself in time. In profuse menstrual loss, endocrine, metabolic, and hemorrhagic disorders must be exlcuded before treatment with progesterone for endometrial hyperplasia. Primary amenorrhea requires detailed examination before diagnosis. Secondary amenorrhea is commonly caused by a disturbance of the hypothalamic-pituitary-ovarian axis due to an emotional disturbance. If pregnancy is eliminated, examination and reassurance are sufficient treatment. Most dysmenorrhea may be treated with mild analgesics and reassurance; in severe cases ovulation may be inhibited by estrogen treatment. Dilation of the cervix should never be attempted. In complaints of vaginal discharge, examination should be made for trichomonas, monilia, gonorrhea, or a forgotten tampon. Requests for contraception should be taken seriously regardless of age. The combined contraceptive pill or Gravigard or copper 7 IUD is the method of choice. Lower abdominal pain caused by pelvic inflammatory disease should be treated early to prevent tubal occlusion after salpingitis. Evidence of higher cervical cancer incidence among women who were sexually active in adolescence suggests routine cervical cytology should be performed. Treatment of adolescents should dispel ignorance and embarrassment with patience and skill.
 ...
PMID:Aspects of student health. Adolescent gynaecology. 83 29

A multicentre randomized open clinical trial was conducted to compare the efficacy and side effects of two regimens of mifepristone with misoprostol, and mifepristone with PG05 for termination of early pregnancy (amenorrhoea < = 49 days). Six-hundred women in early pregnancy, who requested medical abortion were randomly allocated into 3 groups. In group 1 (n = 301), an initial dose of mifepristone 50 mg was given, followed by 25 mg every 12 hours up to a total dose of 150 mg mifepristone, plus a single oral dose of misoprostol 600 micrograms in the morning of the third day. In group 2 (n = 150), the same regimen of mifepristone was given, but dl-15-methyl PGF2 alpha (PG05) 1 mg vaginal suppository was inserted on the third day. In group 3 (n = 149), a single dose of mifepristone 200 mg was given and misoprostol 600 micrograms was used as in group 1. The complete abortion rate were 94.4%, 97.3%, and 94.6% for group 1, 2 and 3, respectively. 3.0, 2.0 and 2.7% of women had incomplete abortion, and 1.7, 0.7 and 2.0% of women in the 3 groups were treatment failures; in the remaining 1% in group 1 and 0.7% in group 3, treatment outcome could not be determined. There were no significant differences among the 3 groups. Lower abdominal pain was the main complaint which was reported by 82% of the subjects after PGs administration. The incidence of diarrhoea in PG05 group (38.7%) was significantly higher than that in the other two groups (21.6 and 20.1%) (P < 0.001), and so was vomiting. It was concluded that misoprostol, as an orally effective prostaglandin, in combination with mifepristone for induced abortion of early pregnancy was as effective as PG05 vaginal suppository. Besides, it has advantages of convenience of use, less side effects, easy storage and transfer, and low cost.
 ...
PMID:Termination of early pregnancy by two regimens of mifepristone with misoprostol and mifepristone with PG05--a multicentre randomized clinical trial in China. 770 93